Primary and metastatic brain tumours may result in an altered exposure of normal cellular components to the immune system inducing an immune response measurable in autoantibodies. One potential immunogenic molecule is sulphatide, the major acidic glycolipid in myelin. Thirty-eight sera from 31 patients with primary and metastatic brain tumours have, therefore, been analyzed for the presence of antisulphatide antibodies by an ELISA performed on thin layer chromatography plates. Twenty-eight of the thirty-eight sera (74%) showed a positive antibody titre to sulphatide. The antibody titres were significantly higher (p < 0.01) in sera from patients with primary brain tumours than in sera from those with metastases. The study lends support to the possibility that antisulphatide antibodies could contribute to tissue damage and this might facilitate the invasive growth in primary brain tumours by demyelination. However, the pathogenic significance of these autoantibodies remains to be further elucidated.

1.
Arvin B, Neville LF, Barone FC, Feuerstein GZ: The role of inflammation and cytokines in brain injury. Neurosci Biobehav Rev 1996;20:445–452.
2.
Martin R, McFarland HF, McFarlin DE: Immunological aspects of demyelinating diseases. Annu Rev Immunol 1992;10:153–187.
3.
Svennerholm L, Bostrom K, Fredman P, Jungbjer B, Mansson JE, Rynmark BM: Membrane lipids of human peripheral nerve and spinal cord. Biochim Biophys Acta 1992;1128/1:1–7.
4.
Fredman P, Lycke J, Andersen O, Vrethem M, Ernerudh J, Svennerholm L: Peripheral neuropathy associated with monoclonal IgM antibody to glycolipids with a terminal glucuronyl-3-sulfate epitope. J Neurol 1993;240:381–387.
5.
Ilyas AA, Mithen FA, Dalakas MC, Wargo M, Chen ZW, Bielory L, Cook SD: Antibodies to sulfated glycolipids in Guillain-Barré syndrome. J Neurol Sci 1991;105/1:108–117.
6.
Pestronk A, Li F, Griffin J, Feldman EL, Cornblath D, Trotter J, Zhu S, Yee WC, Phillips D, Peeples DM, Winslow BS: Polyneuropathy syndromes associated with serum antibodies to sulfatide and myelin-associated glycoprotein. Neurology 1991;41:357–362.
7.
De Gasperi R, Angel M, Sosa G, Patarca R, Battistini S, Lamoreux MR, Raghavan S, Kowall NW, Smith KH, Fletcher MA, Kolodny EH: Intrathecal synthesis of anti-sulfatide IgG is associated with peripheral nerve disease in acquired immunodeficiency syndrome. AIDS Res Hum Retroviruses 1996;12/3:205–211.
8.
Aotsuka S, Okawa-Takatsuji M, Uwatoko S, Yokohari R, Ikeda Y, Toda G: Antibodies against sulphatide in sera from patients with autoimmune rheumatic diseases. Clin Exp Immunol 1992;87:438–443.
9.
Buschard K, Josefsen K, Horn T, Fredman P: Sulphatide and sulphatide antibodies in insulin-dependent diabetes mellitus. Lancet 1993;342:840.
10.
Ferrari S, Morbin M, Nobile-Orazio E, Musso A, Tomelleri G, Bertolasi L, Rizzuto N, Monaco S: Antisulfatide polyneuropathy: Antibody-mediated complement attack on peripheral myelin. Acta Neuropathol (Berl) 1998;96:569–574.
11.
Qin Z, Guan Y: Experimental polyneuropathy produced in guinea-pigs immunized against sulfatide. Neuroreport 1997;8:2867–2870.
12.
Gisslen M, Lekman A, Fredman P: High levels in serum, but no signs of intrathecal synthesis of anti-sulfatide antibodies in HIV-1 infected individuals with or without central nervous system complications: J Neuroimmunol 1999;94/1–2:153–156.
13.
Holmin S, Sonderlund J, Biberfeld P, Mathiesen T: Intracerebral inflammation after human brain contusion. Neurosurgery 1998;42:291–299.
14.
Marcus DM, Latov N, Hsi BP, Gillard BK: Measurement and significance of antibodies against GM1 ganglioside. Report of a workshop, 18 April 1989, Chicago, IL, USA. J Neuroimmunol 1989;25/2–3:255–259.
15.
Zielasek J, Ritter G, Magi S, Hartung HP, Toyka KV: A comparative trial of antiglycoconjugate antibody assays: IgM antibodies to GM1. J Neurol 1994;241:475–480.
16.
Gleeson PA: Glycoconjugates in autoimmunity. Biochim Biophys Acta 1994;1197/3:237–255.
17.
Fredman P, Wallin A, Blennow K, Davidsson P, Gottfries CG, Svennerholm L: Sulfatide as a biochemical marker in cerebrospinal fluid of patients with vascular dementia. Acta Neurol Scand 1992;85/2:103–106.
18.
Sakakibara N, Gasa S, Kamio K, Makita A, Koyanagi T: Association of elevated sulfatides and sulfotransferase activities with human renal cell carcinoma. Cancer Res 1989;49:335–339.
19.
Kolodny EH, Fluharty AL: Metachromatic leucodystrophy and multiple sulphatase deficiency: sulphatide lipidosis; in Scriver CR, Beaudlet AL, Sly WS, Valle D (eds): The Metabolic and Molecular Bases of Inherited Disease. New York, McGraw-Hill, 1995, pp 2693–2740.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.